BioSpace News Archive

GenesisCare, one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom, announced it expanded its partnership with ViewRay, Inc.

Erectile dysfunction shockwave therapy is a non-invasive therapeutic technique used for the treatment of erectile dysfunction.

Fact MR: The global cosmetic dentistry market is expected to steadily grow in coming years. As per Fact.MR, the cosmetic dentistry will showcase growth at 6% CAGR over the forecast period 2021-2031.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the China National Intellectual Property Administration has issued a notice of allowance, informing the company that a patent application relating to the anti-FcγRllB antibody BI-1206 is granted contingent on payment of the issue fee.

DeepVerge, announces the successful completion of Phase 3 field trials in which Microtox® PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.

Advanced Aesthetic Technologies, Inc. is proud to announce the initiation of a clinical trial for their Algeness® VL Filler in China in partnership with Lanzhou Biotechnique Development Co., LTD and their parent company China National Biotec Group Co., LTD This study aims to evaluate the effectiveness and safety of Algeness® VL in the treatment of moderate to severe nasolabial folds with commercially available hyaluronic acid fillers for injection as a control.

A string of varied growth factors are set to propel the growth trajectory of global glycan analysis market over the forecast period of 2020 to 2030.

Fosun Kite Biotechnology announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel has been approved by China National Medical Products Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

LumiraDx, a next-generation point of care diagnostics testing company, confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

About ViaDerma, Inc. ViaDerma, Inc. is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.